Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer

Gynecologic Oncology

Volumn 93, Issue 3, 2004, Pages 715-717

  Markman, Maurie ^a   Webster, Kenneth ^a   Zanotti, Kristine ^a   Peterson, Gertrude ^a   Kulp, Barbara ^a   Belinson, Jerome ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CA 125 tumor antigen; Cancer chemotherapy; Ovarian cancer; Primary peritoneal cancer

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MEGESTROL ACETATE; PACLITAXEL; TAMOXIFEN; TOPOTECAN; TUMOR MARKER;

ACCURACY; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL;

AGED; CA-125 ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 2942633480     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.003     Document Type: Article

References (12)

1. Rustin G.J.S., Nelstrop A.E., Bentzen S.M., Piccart M.J., Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Ann. Oncol. 10:1999;S21-S27
2. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol. Oncol. 44:1992;207-212
3. Frasci G., Conforti S., Zullo F., Mastrantonio P., Comella G., Comella P., et al. A risk model for ovarian carcinoma patients using CA 125. Time to normalization renders second-look laparotomy redundant. Cancer. 77:1996;1122-1130
4. van Dalen A., Favier J., Burges A., Hasholzner U., de Bruijn H.W.A., Dobler-Girdziunaite D., et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol. Oncol. 79:2000;444-450
5. Makar A.P., Kristensen G.B., Bormer O.P., Trope C.G. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol. Oncol. 49:1993;73-79
6. Rustin G.J.S., et al. for the North Thames Cooperative Group Use of CA-125 to predict survival of patients with ovarian carcinoma. J. Clin. Oncol. 7:1989;1667-1671
7. Rustin G.J.S., Marples M., Nelstrop A.E., Mahmoudi M., Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J. Clin. Oncol. 19:2001;4054-4057
8. Wilder J.L., Pavlik E., Straughn J.M., Kirby T., Higgins R.V., DePriest P.D., et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol. Oncol. 89:2003;233-235
9. Vergote I., et al. on behalf of the Gynecologic Cancer Intergroup Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. J. Natl. Cancer Inst. 92:2000;1534-1535
10. Rubin S.C., Hoskins W.J., Hakes T.B., Markman M., Reichman B.S., Chapman D., et al. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am. J. Obstet. Gynecol. 160:1989;667-671
11. Bridgewater J.A., Nelstrop A.E., Rustin G.J.S., Gore M.E., McGuire W.P., Hoskins W.J. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J. Clin. Oncol. 17:1999;501-508
12. Rustin G.J.S., Nelstrop A.E., Bentzen S.M., Bond S.J., McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J. Clin. Oncol. 18:2000;1733-1739